

Kiang-Teck J Yeo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4649885/publications.pdf>

Version: 2024-02-01

89
papers

7,535
citations

159525

30
h-index

56687

83
g-index

93
all docs

93
docs citations

93
times ranked

6376
citing authors

#	ARTICLE	IF	CITATIONS
1	Analytical and Clinical Evaluation of the Semi-quantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer. <i>American Journal of Clinical Pathology</i> , 2022, 157, 109-118.	0.4	5
2	Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. <i>Cancer</i> , 2022, 128, 1649-1657.	2.0	5
3	Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. <i>Clinical Chemistry</i> , 2022, 68, 771-781.	1.5	8
4	Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. <i>Anesthesia and Analgesia</i> , 2022, 135, 929-940.	1.1	1
5	Evaluation of the Truview Easy Check COVID-19 IgM/IgG Lateral Flow Device for Rapid Anti-SARS-CoV-2 Antibody Detection. <i>American Journal of Clinical Pathology</i> , 2021, 155, 286-295.	0.4	11
6	Is Adding IgM Antibody to Polymerase Chain Reaction Testing Useful for COVID-19 Travel Screening?. <i>American Journal of Clinical Pathology</i> , 2021, 155, 321-323.	0.4	3
7	Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG lateral flow assay. <i>PLoS ONE</i> , 2021, 16, e0247797.	1.1	20
8	Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 1505-1516.	0.6	6
9	Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction. <i>American Journal of Obstetrics & Gynecology</i> , 2021, 3, 100394.	1.3	5
10	Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. <i>Oncologist</i> , 2021, 26, e2042-e2052.	1.9	12
11	Triiodothyroacetic Acid Cross-React With Measurement of Triiodothyronine (T3) on Various Immunoassay Platforms. <i>American Journal of Clinical Pathology</i> , 2021, . .	0.4	3
12	Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 1343.	1.1	2
13	Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. <i>Pharmacogenomics Journal</i> , 2020, 20, 126-135.	0.9	14
14	Evaluation of interference effects from hemolysis, icterus and lipemia on the Roche Elecsys Anti-SARS-CoV-2 assay. <i>Clinica Chimica Acta</i> , 2020, 509, 293-294.	0.5	3
15	Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer. <i>American Journal of Clinical Pathology</i> , 2020, 154, 620-626.	0.4	26
16	False-Positive Hepatitis B Surface Antibody Results: An Example of Reagent Carryover. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 429-431.	0.6	2
17	Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 368-376.	2.3	11
18	Implementation of pharmacogenomic testing in oncology care (PhOCUS): study protocol of a pragmatic, randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097411.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Validation of Soluble Fms-Like Tyrosine Kinase-1 (sFlt-1) and Placental Growth Factor (PlGF) Assays on Cobas e602 System. <i>American Journal of Clinical Pathology</i> , 2020, 154, S12-S13.	0.4	0
20	Development of a Nonradioactive Platelet Serotonin Uptake and Release Assay by Micro-Liquid Chromatography Tandem Mass Spectrometry Using Minimal Blood Volume. <i>American Journal of Clinical Pathology</i> , 2019, 152, 718-724.	0.4	2
21	The ImPre^{SS} Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1179-1183.	2.3	15
22	Evaluation of a New Generation Automated Assay for 25-Hydroxy Vitamin D Based on Competitive Protein Binding. <i>journal of applied laboratory medicine, The</i> , 2019, 4, 247-253.	0.6	6
23	Analytical Differences in Intraoperative Parathyroid Hormone Assays. <i>journal of applied laboratory medicine, The</i> , 2019, 3, 788-798.	0.6	6
24	Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients. <i>Hypertension</i> , 2019, 73, 868-877.	1.3	36
25	Smith-Lemli-Opitz Syndrome in a newborn infant with developmental abnormalities and low endogenous cholesterol. <i>Clinica Chimica Acta</i> , 2018, 479, 208-211.	0.5	1
26	Analytical validation of soluble fms-like tyrosine and placental growth factor assays on BÂ-RÂ-AÂ-HÂ-MÂ-S KRYPTOR Compact Plus automated immunoassay platform. <i>Pregnancy Hypertension</i> , 2018, 11, 66-70.	0.6	11
27	Reengineering Critical Laboratory Testing for Timely Chemotherapeutic Management. <i>journal of applied laboratory medicine, The</i> , 2018, 3, 240-249.	0.6	1
28	Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. <i>Pregnancy Hypertension</i> , 2018, 14, 110-114.	0.6	9
29	Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. <i>Clinica Chimica Acta</i> , 2018, 483, 308-314.	0.5	6
30	Losing sight of the Forest for the trees: Why clinical laboratories need to perform their own interference studies. <i>Clinica Chimica Acta</i> , 2018, 483, 239-240.	0.5	0
31	Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 859-869.	2.3	68
32	Wellness Initiatives: Benefits and Limitations. <i>Clinical Chemistry</i> , 2017, 63, 1063-1068.	1.5	2
33	Commentary. <i>Clinical Chemistry</i> , 2017, 63, 1329-1330.	1.5	0
34	Validation of an Extensive <i>CYP2D6</i> Assay Panel Based on Invader and TaqMan Copy Number Assays. <i>journal of applied laboratory medicine, The</i> , 2017, 1, 471-482.	0.6	10
35	High-Sensitivity Micro LC-MS/MS Assay for Serum Estradiol without Derivatization. <i>journal of applied laboratory medicine, The</i> , 2016, 1, 14-24.	0.6	18
36	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 172-185.	2.3	146

#	ARTICLE	IF	CITATIONS
37	Diiodothyropropionic acid (DITPA) cross-reacts with thyroid function assays on different immunoassay platforms. <i>Clinica Chimica Acta</i> , 2016, 453, 203-204.	0.5	1
38	89: Development of a Novel Micro LC-MS/MS Method for Assay of Agonist-Induced Release of Endogenous Serotonin from Human Platelets. <i>American Journal of Clinical Pathology</i> , 2015, 143, A052-A052.	0.4	0
39	Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response. <i>International Immunopharmacology</i> , 2015, 27, 249-256.	1.7	33
40	Discrepant serum and urine β -hCG results due to production of β -hCG by a cribriform-morular variant of thyroid papillary carcinoma. <i>Clinica Chimica Acta</i> , 2015, 438, 181-185.	0.5	12
41	Simultaneous Assay of Agonist-Induced Endogenous and Non-Radioactive Isotopic Serotonin Secretion from Small Numbers of Human Platelets By Mass Spectrometry. <i>Blood</i> , 2015, 126, 1055-1055.	0.6	0
42	Clinical evaluation of the QMS \hat{A} Tacrolimus Immunoassay. <i>Clinica Chimica Acta</i> , 2014, 431, 270-275.	0.5	11
43	Automated red cell exchange: a simplified formula for how many red cell units to exchange and validity of haemoglobin S levels measured one to two hours later. <i>Blood Transfusion</i> , 2014, 12 Suppl 1, s145-6.	0.3	2
44	Reducing the risk of hyperammonemia from transfusion of stored red blood cells. <i>Transfusion and Apheresis Science</i> , 2013, 49, 459-462.	0.5	9
45	Clinical Evaluation of the Enterprise Point of Care for Blood Gas Electrolytes and Metabolites. <i>Point of Care</i> , 2013, 12, 127-133.	0.5	4
46	Effect of blood collection tubes on the incidence of artifactual hyperkalemia on patient samples from an outreach clinic. <i>Clinica Chimica Acta</i> , 2012, 413, 1454-1458.	0.5	15
47	A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department. <i>American Heart Journal</i> , 2011, 162, 276-282.e1.	1.2	31
48	Evaluation of a CYP2C19 genotype panel on the GenMark eSensor \hat{A} platform and the comparison to the Autogenomics Infniti \hat{A} , $\text{\textcircled{C}}$ and Luminex CYP2C19 panels. <i>Clinica Chimica Acta</i> , 2011, 412, 1133-1137.	0.5	18
49	Molecular Diagnostic Methods in Pharmacogenomics. , 2011, , 15-34.		0
50	Issues in Translation of Pharmacogenomics into Clinical Practice. , 2011, , 3-14.		0
51	From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. <i>Pharmacogenomics</i> , 2010, 11, 731-737.	0.6	21
52	Characterization of 107 Genomic DNA Reference Materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 835-846.	1.2	98
53	Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. <i>Clinica Chimica Acta</i> , 2009, 406, 143-147.	0.5	22
54	Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. <i>Personalized Medicine</i> , 2009, 6, 315-327.	0.8	27

#	ARTICLE	IF	CITATIONS
55	Pseudohyperkalemia – Is serum or whole blood a better specimen type than plasma?. Clinica Chimica Acta, 2008, 396, 95-96.	0.5	26
56	Validation of a CYP2D6 Genotyping Panel on the NanoChip Molecular Biology Workstation. Clinical Chemistry, 2007, 53, 823-828.	1.5	11
57	Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clinica Chimica Acta, 2006, 367, 196-200.	0.5	36
58	Elecsys NT-ProBNP and BNP Assays: Are There Analytically and Clinically Relevant Differences?. Journal of Cardiac Failure, 2005, 11, S84-S88.	0.7	25
59	Can Exercise-Induced Changes in B-Type Natriuretic Peptides Be Used to Detect Cardiac Ischemia?. Journal of Cardiac Failure, 2005, 11, S59-S64.	0.7	21
60	Evaluation of Imprecision for Cardiac Troponin Assays at Low-Range Concentrations. Clinical Chemistry, 2004, 50, 327-332.	1.5	342
61	Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. Journal of the American College of Cardiology, 2004, 44, 1980-1987.	1.2	132
62	Acute effects of nicotine on serum glucose insulin growth hormone and cortisol in healthy smokers. Metabolism: Clinical and Experimental, 2004, 53, 578-582.	1.5	36
63	Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clinica Chimica Acta, 2003, 338, 107-115.	0.5	276
64	Interferences in Immunoassays for Cardiac Troponin. , 2003, , 187-197.		1
65	Lot-to-Lot Inconsistency of Anticardiolipin Reagents. Clinical Chemistry, 2002, 48, 1625-1626.	1.5	7
66	Lot-to-lot inconsistency of anticardiolipin reagents. Clinical Chemistry, 2002, 48, 1625-6; author reply 1626.	1.5	1
67	Performance of the enhanced Abbott AxSYM Cardiac Troponin I reagent in patients with heterophilic antibodies. Clinica Chimica Acta, 2000, 292, 13-23.	0.5	37
68	Hypoxia augments cytokine (transforming growth factor-beta (TGF- β 2) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clinical and Experimental Immunology, 1999, 115, 176-182.	1.1	179
69	False Increase of Cardiac Troponin I with Heterophilic Antibodies. Clinical Chemistry, 1998, 44, 2212-2214.	1.5	153
70	Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.. Journal of Clinical Investigation, 1996, 98, 1667-1675.	3.9	367
71	Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Bullous Pemphigoid, Dermatitis Herpetiformis, and Erythema Multiforme. Journal of Investigative Dermatology, 1995, 104, 744-749.	0.3	133
72	Keratinocyte-Derived Vascular Permeability Factor (Vascular Endothelial Growth Factor) Is a Potent Mitogen for Dermal Microvascular Endothelial Cells. Journal of Investigative Dermatology, 1995, 105, 44-50.	0.3	215

#	ARTICLE	IF	CITATIONS
73	Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. <i>Obstetrics and Gynecology</i> , 1995, 86, 815-821.	1.2	184
74	Regulation of Vascular Endothelial Growth Factor in Cardiac Myocytes. <i>Circulation Research</i> , 1995, 76, 758-766.	2.0	180
75	Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.. <i>Journal of Experimental Medicine</i> , 1994, 180, 341-346.	4.2	481
76	Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy. <i>American Journal of Ophthalmology</i> , 1994, 118, 445-450.	1.7	1,212
77	Vascular permeability factor (VPF, VEGF) in tumor biology. <i>Cancer and Metastasis Reviews</i> , 1993, 12, 303-324.	2.7	791
78	Synthesis and Secretion of Vascular Permeability Factor/Vascular Endothelial Growth Factor by Human Retinal Pigment Epithelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1993, 193, 631-638.	1.0	370
79	Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing.. <i>Journal of Experimental Medicine</i> , 1992, 176, 1375-1379.	4.2	824
80	Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation. <i>Annals of the New York Academy of Sciences</i> , 1992, 667, 101-111.	1.8	212
81	Differential transport kinetics of chondroitin sulfate and dermatan sulfate proteoglycan by monkey aorta smooth muscle cells. <i>Archives of Biochemistry and Biophysics</i> , 1992, 294, 9-16.	1.4	9
82	Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). <i>Biochemical and Biophysical Research Communications</i> , 1991, 179, 1568-1575.	1.0	72
83	Citrate Anticoagulation during in vivo Simulation of Slow Hemofiltration. <i>Blood Purification</i> , 1990, 8, 177-182.	0.9	17
84	Influence of hypothermic cardiopulmonary bypass on atrial natriuretic factor levels. <i>Canadian Journal of Anaesthesia</i> , 1989, 36, 545-553.	0.7	32
85	Atrial Natriuretic Factor May Mediate the Renal Effects of PEEP Ventilation. <i>Anesthesiology</i> , 1988, 69, 862-869.	1.3	45
86	Two novel endogenous digoxin-like immunoreactive substances isolated from human plasma ultrafiltrate. <i>Biochemical and Biophysical Research Communications</i> , 1987, 148, 623-628.	1.0	24
87	Function of glycoprotein glycans. <i>Trends in Biochemical Sciences</i> , 1985, 10, 78-82.	3.7	183
88	Analysis of the fate of platelet-bound thrombin. <i>Archives of Biochemistry and Biophysics</i> , 1985, 236, 399-410.	1.4	8
89	The action of calcium-dependent protease on platelet surface glycoproteins. <i>Archives of Biochemistry and Biophysics</i> , 1983, 227, 287-301.	1.4	88